The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Claire‐Anne Siegrist, Floriane Auderset et al.|The Lancet Infectious Diseases|2015Cited by 278
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and AfricaAngela Huttner, Claire‐Anne Siegrist, Christophe Combescure et al.|Science Translational Medicine|2017Cited by 64